CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)
Operating activities
Net loss	$ (40,891)	$ (46,683)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	1,288	1,609
Amortization and accretion on investment securities, net	(1,729)	(1,494)
Future royalty payment contingency interest accretion	1,903	1,727
Share-based compensation	15,567	19,547
Loss on disposal of property and equipment	(129)	1,353
Loss on impairment of long-lived assets	4,513
Amortization of right-of-use assets	3,361	2,724
Deferred income taxes	(984)
Changes in operating assets and liabilities:
Receivables from collaborative and licensing arrangements	629	(272)
Prepaid clinical and development services	1,441	(121)
Other prepaid and current assets	3,926	(1,315)
Right-of-use lease assets	(634)	(173)
Other assets	533	3,309
Accounts payable	(38)	354
Accrued personnel-related expenses, accrued clinical and development expenses, and other accrued liabilities	(1,523)	(6,657)
Deferred revenue		(17)
Operating lease liabilities	(4,178)	(1,329)
Unrecognized tax benefits	6,269
Other long-term liabilities	43	1,295
Net cash used in operating activities	(10,633)	(26,143)
Investing activities
Purchases of property and equipment	(142)	(1,811)
Purchases of marketable securities	(103,022)	(134,534)
Maturities of marketable securities	99,762	31,435
Sale of short-term investments and marketable securities		71,377
Proceeds from the sale of property and equipment		1,513
Net cash used in investing activities	(3,402)	(32,020)
Financing activities
Ordinary share repurchases	(445)	(166,787)
Proceeds from the sale of ordinary shares	69
Proceeds from ESPP purchases	375	445
Repurchase of shares to satisfy tax withholding	(2,131)	(1,982)
Net cash used in financing activities	(2,132)	(168,324)
Net decrease in cash, cash equivalents, and restricted cash	(16,167)	(226,487)
Cash, cash equivalents, and restricted cash at beginning of period	40,381	299,008
Cash, cash equivalents, and restricted cash at end of period	24,214	72,521
Supplemental disclosure of cash flow information
Cash paid for income taxes, net	$ 12	14
Supplemental disclosure of non-cash activities
Recognition of tenant improvement allowance assigned to sublease		$ 6,490